SecBot SecBot
SECBOTREPLAY Home › Report › BIOA

BIOA · BioAge Labs announced first participant dosed in QUELL-CV, a Phase 2…

BioAge Labs, Inc. · PRESS-RELEASE filed Jun 16, 2026 at 08:00 ET

At the news

NEUTRALIMPACT 3/10

PRESS-RELEASE filed Jun 16, 2026 at 08:00 ET

BioAge Labs announced first participant dosed in QUELL-CV, a Phase 2 proof-of-concept trial of BGE-102 (NLRP3 inhibitor) for cardiovascular risk reduction. Topline data expected H2 2026, a routine operational milestone with no financial or efficacy data disclosed.

  • First participant dosed in Phase 2 trial QUELL-CV evaluating BGE-102
  • Trial is randomized, double-blind, placebo-controlled, dose-ranging (30/60/90 mg QD) in ~160 participants
  • Primary endpoint: percent change from baseline in hsCRP
  • Topline data anticipated in second half of 2026

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access